[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100642561":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":7,"centralContacts":13,"locations":18,"responsibleParty":69,"collaborators":7,"id":71,"slug":72,"hasResults":73,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":7,"eligibilityCriteria":77,"healthyVolunteers":73,"sex":78,"minAge":79,"maxAge":7,"enrollmentInfo":80,"targetDuration":7,"studyType":83,"phases":7,"briefSummary":84,"conditions":85,"keywords":87,"overallStatus":34,"whyStopped":7,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":101},{"fullName":5,"class":6},"Camurus AB","INDUSTRY",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":7},"DRUG","Octreotide subcutaneous depot","Commercially available octreotide subcutaneous depot treatment administered by participants for a maximum duration up to 2 years in the study",[14],{"name":5,"role":15,"phone":16,"phoneExt":7,"email":17},"CONTACT","+46 46 286 57 30","medicalinfo@camurus.com",[19,32,42,51,60],{"facility":20,"status":21,"city":22,"state":7,"zip":23,"country":24,"countryCode":25,"cosmosGeoPoint":26,"geoPoint":31,"contacts":7},"Universitaetsklinikum Aachen","NOT_YET_RECRUITING","Aachen","52074","Germany","DE",{"type":27,"coordinates":28},"Point",[29,30],6.08342,50.77664,{"lat":30,"lon":29},{"facility":33,"status":34,"city":35,"state":7,"zip":36,"country":24,"countryCode":25,"cosmosGeoPoint":37,"geoPoint":41,"contacts":7},"Universitaetsklinikum Leipzig","RECRUITING","Leipzig","04103",{"type":27,"coordinates":38},[39,40],12.37129,51.33962,{"lat":40,"lon":39},{"facility":43,"status":21,"city":44,"state":7,"zip":45,"country":24,"countryCode":25,"cosmosGeoPoint":46,"geoPoint":50,"contacts":7},"Fachpraxis für Innere Medizin, Endokrinologie und Diabetologie","Magdeburg","39110",{"type":27,"coordinates":47},[48,49],11.63189,52.13129,{"lat":49,"lon":48},{"facility":52,"status":21,"city":53,"state":7,"zip":54,"country":24,"countryCode":25,"cosmosGeoPoint":55,"geoPoint":59,"contacts":7},"Medicover Neuroendokrinologie MVZ","München","81667",{"type":27,"coordinates":56},[57,58],13.31243,51.60698,{"lat":58,"lon":57},{"facility":61,"status":21,"city":62,"state":7,"zip":63,"country":24,"countryCode":25,"cosmosGeoPoint":64,"geoPoint":68,"contacts":7},"Universitätsklinikum Würzburg","Würzburg","97080",{"type":27,"coordinates":65},[66,67],9.95121,49.79391,{"lat":67,"lon":66},{"type":70,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100642561","an-observational-study-of-octreotide-subcutaneous-depot-in-patients-with-acromegaly-100642561",false,"NCT07583563","An Observational Study of Octreotide Subcutaneous Depot in Patients With Acromegaly","A Multi-Center, Multinational, Observational Study of Octreotide Subcutaneous Depot for the Treatment of Patients With Acromegaly","Inclusion Criteria:\n\n* Have started or will be starting treatment with octreotide SC depot for acromegaly\n\nExclusion Criteria:\n\n* Have started or will be starting treatment with octreotide SC depot for other conditions not related to acromegaly\n* Currently taking part in an interventional clinical trial or is still within a 30-day washout period from the end of taking part in an interventional clinical trial.","ALL","18 Years",{"count":81,"type":82},200,"ESTIMATED","OBSERVATIONAL","The purpose of this study is to collect long-term (up to two years) safety and effectiveness of octreotide subcutaneous depot in patients with acromegaly in the real-world setting.",[86],"Acromegaly",[11,86,88,89,90,91],"Observational","Real-world","Safety","Tolerability","2026-06-26",{"date":94,"type":95},"2026-06-30","ACTUAL",{"date":97,"type":95},"2026-06-05",{"date":99,"type":82},"2029-06",{"name":5,"class":6},5]